R. Adinin

648 total citations
9 papers, 496 citations indexed

About

R. Adinin is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, R. Adinin has authored 9 papers receiving a total of 496 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 5 papers in Pulmonary and Respiratory Medicine and 3 papers in Cancer Research. Recurrent topics in R. Adinin's work include Cancer Treatment and Pharmacology (6 papers), Colorectal Cancer Treatments and Studies (5 papers) and Advanced Breast Cancer Therapies (2 papers). R. Adinin is often cited by papers focused on Cancer Treatment and Pharmacology (6 papers), Colorectal Cancer Treatments and Studies (5 papers) and Advanced Breast Cancer Therapies (2 papers). R. Adinin collaborates with scholars based in United States, Brazil and Japan. R. Adinin's co-authors include Robert A. Wolff, Scott Kopetz, Jeffrey S. Morris, Cathy Eng, James L. Abbruzzese, Paulo M. Hoff, Katrina Y. Glover, Hai T. Tran, Sijin Wen and Lee M. Ellis and has published in prestigious journals such as Journal of Clinical Oncology.

In The Last Decade

R. Adinin

9 papers receiving 481 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
R. Adinin United States 6 314 234 132 113 100 9 496
Ruoyu Shi China 5 256 0.8× 142 0.6× 159 1.2× 67 0.6× 201 2.0× 15 473
Concetta Sgarra Italy 7 156 0.5× 232 1.0× 130 1.0× 34 0.3× 113 1.1× 7 424
Hokahiro Katayama Japan 11 173 0.6× 160 0.7× 137 1.0× 66 0.6× 87 0.9× 33 518
Tianhong Su China 15 171 0.5× 418 1.8× 162 1.2× 99 0.9× 269 2.7× 22 748
Jobst C. von Einem Germany 15 456 1.5× 107 0.5× 116 0.9× 178 1.6× 118 1.2× 33 659
Giulia Orsi Italy 12 220 0.7× 171 0.7× 89 0.7× 148 1.3× 113 1.1× 34 514
R Macchi Italy 7 233 0.7× 209 0.9× 109 0.8× 61 0.5× 101 1.0× 14 657
Bettina Schwarz Germany 14 217 0.7× 193 0.8× 50 0.4× 105 0.9× 129 1.3× 20 756
Yusaku Hori Japan 7 369 1.2× 127 0.5× 234 1.8× 166 1.5× 97 1.0× 16 710

Countries citing papers authored by R. Adinin

Since Specialization
Citations

This map shows the geographic impact of R. Adinin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R. Adinin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R. Adinin more than expected).

Fields of papers citing papers by R. Adinin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by R. Adinin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R. Adinin. The network helps show where R. Adinin may publish in the future.

Co-authorship network of co-authors of R. Adinin

This figure shows the co-authorship network connecting the top 25 collaborators of R. Adinin. A scholar is included among the top collaborators of R. Adinin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with R. Adinin. R. Adinin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

9 of 9 papers shown
1.
Sankhala, Kamalesh K., Akira Mita, R. Adinin, et al.. (2009). A phase I pharmacokinetic (PK) study of MBP-426, a novel liposome encapsulated oxaliplatin. Journal of Clinical Oncology. 27(15_suppl). 2535–2535. 55 indexed citations
2.
Kopetz, Scott, Paulo M. Hoff, Jeffrey S. Morris, et al.. (2009). Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer: Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic Resistance. Journal of Clinical Oncology. 28(3). 453–459. 376 indexed citations
3.
Overman, Michael J., Gauri R. Varadhachary, Emily Lin, et al.. (2008). Final response data of a phase II study of capecitabine and oxaliplatin (CAPOX) in advanced adenocarcinoma of the small bowel or ampulla of Vater. Journal of Clinical Oncology. 26(15_suppl). 4538–4538. 3 indexed citations
4.
Sankhala, Kamalesh K., Chris H. Takimoto, Akira Mita, et al.. (2008). Two phase I, pharmacokinetic (PK) and pharmacodynamic (PD) studies of TAS-109, a novel nucleoside analogue with 14 days and 7 days continuous infusion (CI) schedules. Journal of Clinical Oncology. 26(15_suppl). 2577–2577. 3 indexed citations
5.
Kopetz, Scott, Cathy Eng, Robert A. Wolff, et al.. (2007). Phase II study of infusional 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) plus bevacizumab as first-line treatment for metastatic colorectal cancer. Journal of Clinical Oncology. 25(18_suppl). 4089–4089. 6 indexed citations
6.
Mejia, Jaime, Banu Arun, R. Adinin, et al.. (2006). Phase III study of docetaxel weekly (DW) versus every 3 weeks (D) in patients with metastatic breast cancer: Final results. Journal of Clinical Oncology. 24(18_suppl). 574–574. 5 indexed citations
7.
8.
Kopetz, Scott, James L. Abbruzzese, Cathy Eng, et al.. (2006). Preliminary results from a phase II study of infusional 5-FU, leucovorin, and irinotecan (FOLFIRI) plus bevacizumab as first-line treatment for metastatic colorectal cancer (mCRC). Journal of Clinical Oncology. 24(18_suppl). 3579–3579. 20 indexed citations
9.
Amin, Sapna, et al.. (2006). Prospective study of incidence and severity of epiphora and canalicular stenosis in patients with metastatic breast cancer receiving docetaxel. Journal of Clinical Oncology. 24(18_suppl). 659–659. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ruoyu Shi Breakdown of academic impact, for papers by Concetta Sgarra Breakdown of academic impact, for papers by Hokahiro Katayama Breakdown of academic impact, for papers by Tianhong Su Breakdown of academic impact, for papers by Jobst C. von Einem Breakdown of academic impact, for papers by Giulia Orsi Breakdown of academic impact, for papers by R Macchi Breakdown of academic impact, for papers by Bettina Schwarz Breakdown of academic impact, for papers by Yusaku Hori
Rankless by CCL
2026